MA46988A1 - Liquid formulation of anti-tnf alpha antibodies - Google Patents
Liquid formulation of anti-tnf alpha antibodiesInfo
- Publication number
- MA46988A1 MA46988A1 MA46988A MA46988A MA46988A1 MA 46988 A1 MA46988 A1 MA 46988A1 MA 46988 A MA46988 A MA 46988A MA 46988 A MA46988 A MA 46988A MA 46988 A1 MA46988 A1 MA 46988A1
- Authority
- MA
- Morocco
- Prior art keywords
- liquid formulation
- tnf alpha
- alpha antibodies
- antibodies
- tnf
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title abstract 2
- 229960002964 adalimumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/464438—Tumor necrosis factors [TNF], CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne une formulation liquide d'un anticorps anti-tnf alpha, en particulier l'adalimumab.The present invention relates to a liquid formulation of an anti-tnf alpha antibody, in particular adalimumab.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170033188 | 2017-03-16 | ||
PCT/KR2018/003097 WO2018169348A1 (en) | 2017-03-16 | 2018-03-16 | Liquid formulation of anti-tnf alpha antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
MA46988A1 true MA46988A1 (en) | 2020-06-30 |
Family
ID=63522490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA46988A MA46988A1 (en) | 2017-03-16 | 2018-03-16 | Liquid formulation of anti-tnf alpha antibodies |
Country Status (15)
Country | Link |
---|---|
JP (2) | JP7109849B2 (en) |
KR (2) | KR20180106974A (en) |
CN (1) | CN110621303A (en) |
AU (1) | AU2018236651B2 (en) |
BR (1) | BR112019019162A2 (en) |
CO (1) | CO2019010860A2 (en) |
MA (1) | MA46988A1 (en) |
MX (1) | MX2019010895A (en) |
MY (1) | MY197202A (en) |
NZ (1) | NZ757965A (en) |
PH (1) | PH12019502075A1 (en) |
RU (1) | RU2756619C2 (en) |
UA (1) | UA123847C2 (en) |
WO (1) | WO2018169348A1 (en) |
ZA (1) | ZA201906696B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112021015034A2 (en) * | 2019-02-18 | 2021-10-05 | Eli Lilly And Company | THERAPEUTIC ANTIBODY FORMULATION |
TW202102260A (en) * | 2019-03-21 | 2021-01-16 | 美商再生元醫藥公司 | Stabilized formulations containing anti-il-33 antibodies |
US20230173068A1 (en) * | 2020-02-20 | 2023-06-08 | Bio-Thera Solutions, Ltd. | ANTI-TNF-a ANTIBODY FORMULATION, PREPARATION METHOD THEREFOR AND USE THEREOF |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2815689C (en) * | 2010-11-11 | 2016-11-22 | Abbvie Biotechnology Ltd. | Improved high concentration anti-tnf.alpha. antibody liquid formulations |
UY34105A (en) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | STABLE LIQUID FORMULATION OF ETANERCEPT |
KR20160105535A (en) * | 2012-03-07 | 2016-09-06 | 카딜라 핼쓰캐어 리미티드 | Pharmaceutical Formulations of TNF-Alpha Antibodies |
BR112015004984A2 (en) | 2012-09-07 | 2017-07-04 | Coherus Biosciences Inc | stable aqueous formulations of adalimumab |
CN105051064A (en) * | 2013-01-24 | 2015-11-11 | 葛兰素史克知识产权开发有限公司 | Tnf-alpha antigen-binding proteins |
CN105025925A (en) | 2013-03-15 | 2015-11-04 | 拜尔健康护理有限责任公司 | Anti-prolactin receptor antibody formulations |
WO2015134406A1 (en) | 2014-03-03 | 2015-09-11 | La Jolla Biologics, Inc. | Stable aqueous recombinant protein formulations |
WO2015151115A1 (en) * | 2014-04-02 | 2015-10-08 | Intas Pharmaceuticals Limited | Liquid pharmaceutical composition of adalimumab |
LT2946765T (en) * | 2014-05-23 | 2016-11-25 | Ares Trading S.A. | Liquid pharmaceutical composition |
US9821059B2 (en) | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
HUP1400510A1 (en) * | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Pharmaceutical anti-tnfalpha antibody formulation |
WO2016120413A1 (en) * | 2015-01-28 | 2016-08-04 | Mabxience S.A. | Pharmaceutical formulations for anti-tnf-alpha antibodies |
WO2016162819A1 (en) * | 2015-04-07 | 2016-10-13 | Lupin Limited | Stable aqueous pharmaceutical composition of anti-tnf alpha antibody |
-
2018
- 2018-03-16 MA MA46988A patent/MA46988A1/en unknown
- 2018-03-16 BR BR112019019162A patent/BR112019019162A2/en active Search and Examination
- 2018-03-16 NZ NZ757965A patent/NZ757965A/en unknown
- 2018-03-16 MY MYPI2019005331A patent/MY197202A/en unknown
- 2018-03-16 WO PCT/KR2018/003097 patent/WO2018169348A1/en active Application Filing
- 2018-03-16 AU AU2018236651A patent/AU2018236651B2/en active Active
- 2018-03-16 KR KR1020180031016A patent/KR20180106974A/en active Application Filing
- 2018-03-16 RU RU2019130728A patent/RU2756619C2/en active
- 2018-03-16 JP JP2019551275A patent/JP7109849B2/en active Active
- 2018-03-16 MX MX2019010895A patent/MX2019010895A/en unknown
- 2018-03-16 UA UAA201909838A patent/UA123847C2/en unknown
- 2018-03-16 CN CN201880031705.6A patent/CN110621303A/en active Pending
-
2019
- 2019-09-12 PH PH12019502075A patent/PH12019502075A1/en unknown
- 2019-09-30 CO CONC2019/0010860A patent/CO2019010860A2/en unknown
- 2019-10-10 ZA ZA2019/06696A patent/ZA201906696B/en unknown
-
2020
- 2020-08-05 KR KR1020200098144A patent/KR102342292B1/en active IP Right Grant
-
2022
- 2022-05-06 JP JP2022076654A patent/JP2022097600A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU2018236651A1 (en) | 2019-10-31 |
MY197202A (en) | 2023-05-31 |
AU2018236651B2 (en) | 2020-12-10 |
ZA201906696B (en) | 2020-08-26 |
BR112019019162A2 (en) | 2020-04-14 |
KR20180106974A (en) | 2018-10-01 |
RU2019130728A3 (en) | 2021-04-16 |
JP2022097600A (en) | 2022-06-30 |
MX2019010895A (en) | 2019-11-05 |
CO2019010860A2 (en) | 2020-01-17 |
KR20200096472A (en) | 2020-08-12 |
UA123847C2 (en) | 2021-06-09 |
RU2756619C2 (en) | 2021-10-04 |
WO2018169348A1 (en) | 2018-09-20 |
CN110621303A (en) | 2019-12-27 |
PH12019502075A1 (en) | 2020-09-14 |
NZ757965A (en) | 2022-07-01 |
KR102342292B1 (en) | 2021-12-24 |
JP7109849B2 (en) | 2022-08-01 |
JP2020510079A (en) | 2020-04-02 |
RU2019130728A (en) | 2021-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA53356B1 (en) | Subcutaneous anti-cd38 antibody formulations and uses thereof | |
MA44334A (en) | ANTIBODY CONJUGATES INCLUDING A TOLL-TYPE RECEPTOR AGONIST | |
CL2018003520A1 (en) | Anti-b7-h3 antibodies and antibody and drug conjugates. | |
CL2022000027A1 (en) | PCSK9 antagonist compounds. (Application divisional 202003257). | |
MA42542B1 (en) | Molecules Binding to pd-1 and Corresponding Methods of Use | |
MX2018012648A (en) | Antibody-containing preparation. | |
MA40801A1 (en) | Anti-cd3 antibody, anti-cd123 antibody and bispecific antibodies binding specifically to cd3 and / or cd123 | |
MA40576B1 (en) | Anti-her2 antibodies and immunoconjugates | |
MA44594B1 (en) | Anti-ctla-4 Antibodies and Methods of Use thereof | |
MA45450B1 (en) | Anti-cd19 antibody formulations | |
MA38632A1 (en) | Anti-transferrin receptor antibody and methods of use | |
EA201991701A1 (en) | COMPOSITION BASED ON MONOCLONAL ANTIBODY TO RSV | |
IN2012DN05237A (en) | ||
MA35009B1 (en) | ANTI-SCLERROTIN ANTIBODY CRYSTALS AND FORMULATIONS THEREOF | |
MA38828A1 (en) | Antibodies to plasminogen activator inhibitor type 1 (pai-1) and their uses | |
CO6270369A2 (en) | NEW SPECIFIC ANTIBODIES OF BETA-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC OR DRUG AGENTS | |
MA37946A1 (en) | Treatment of rheumatoid arthritis | |
MA44645B1 (en) | Combined treatment of an anti-cd20 antibody with a bcl-2 inhibitor and an mdm2 inhibitor | |
MX2022001146A (en) | Anti-pvrig antibodies formulations and uses thereof. | |
MA46988A1 (en) | Liquid formulation of anti-tnf alpha antibodies | |
MA38413A1 (en) | Pan-elr + cxc chemokine antibody | |
EA201992027A1 (en) | WATER COMPOSITION OF ANTIBODIES AGAINST PD-L1 | |
EA202092508A1 (en) | COMPOSITIONS BASED ON ANTIBODIES TO HUMAN PD-L1 | |
PH12014501985B1 (en) | Il-17 antibody formulation | |
MA45831B1 (en) | ANTI-BEDBUG MONOCLONAL ANTIBODIES AND METHODS OF PRODUCTION AND USE THEREOF |